Pacritinib is now included as a recommended treatment for myeloproliferative neoplasms with specificity for JAK2 and IRAK1 in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice ...

The FDA has placed a full clinical hold on pacritinib following reports of patient deaths related to intracranial hemorrhage, cardiac failure and cardiac arrest in the phase 3 PERSIST-2 trial. The FDA ...

CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating ...

Pacritinib safely improved disease-related symptoms and reduced spleen volume in patients with myelofibrosis who had pre-existing anemia and thrombocytopenia, according to phase 2 study results.

Author(s)Mascarenhas J, Virtgaym E, Stal M, et al. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol. 2018, 97(8 ...

The clinical hold on pacritinib was recently lifted by the US Food and Drug Administration (FDA). The US Food and Drug Administration’s (FDA) clinical hold on trials for pacritinib were lifted, ...

Baxter International Inc. BAX and CTI BioPharma CTIC recently presented clinical data from PERSIST -1 -- a study which compares the efficacy and safety of pacritinib with that of the best available ...

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (NYSE: BAX) today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, ...

The investigational agent pacritinib (CTI BioPharma) holds promise as a treatment option for patients with myelofibrosis and baseline thrombocytopenia, and previous concerns that led to a hold on ...

CTI BioPharma said today it has regained worldwide development and commercialization rights to the Phase III myelofibrosis drug candidate pacritinib from Baxalta—now a Shire subsidiary—after the two ...

Please provide your email address to receive an email when new articles are posted on . The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in ...